Olmetec (Olmesartan Medoxomil)

Olmesartan medoxomil is an ARB that targets the renin‑angiotensin‑aldosterone system to lower blood pressure.

• Hypertension: helps lower systolic and diastolic blood pressure in adults.
• Heart failure: used as part of combination therapy to improve cardiac output.
• Diabetic nephropathy: slows progression of kidney damage associated with diabetes.

• Olmesartan medoxomil is a selective antagonist of the angiotensin II type 1 (AT1) receptor. By blocking AT1, it prevents angiotensin II‑mediated vasoconstriction, aldosterone release, and sympathetic activation, leading to vasodilation, reduced sodium and water retention, and ultimately lower systemic blood pressure.

Olmesartan medoxil is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Dizziness
• Headache
• Fatigue
• Nasal congestion
• Diarrhea

Serious or Rare Side Effects

• Angio‑edema
• Hyperkalemia
• Acute kidney injury
• Severe hypotension
• Liver enzyme elevation

Olmesartan medoxomil should be used with caution in several clinical situations.

• Pregnancy: contraindicated due to risk of fetal toxicity.
• Renal impairment: dose adjustment may be needed.
• Hyperkalemia: monitor serum potassium levels.
• Concomitant diuretics: may increase risk of hypotension.
• Drug‑induced liver injury: discontinue if liver enzymes rise markedly.
• Store at ambient temperature: keep in original packaging, protect from moisture.

Olmesartan medoxomil can interact with several other medicines.

Major Interactions (Avoid)

• Aliskiren combined with ACE inhibitors or ARBs in diabetic patients.
• Potassium‑sparing diuretics (e.g., spironolactone) – risk of hyper‑kalaemia.

Moderate Interactions (Monitor Closely):

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) – may blunt antihyol

-     ");